Korean Sky Labs Boosts Global Rollout of Cuffless BP Monitors
Sky Labs, a South Korean digital health firm, expects faster international market entry for its cuffless blood pressure monitoring technology. The company reports growing clinical evidence and rapid adoption in Korea drive interest from global partners.
Global Ambition Driven by Evidence
Sky Labs, a South Korean digital health company, anticipates an acceleration in its global market expansion. The firm states that increasing clinical evidence for its cuffless blood pressure monitoring technology, CART BP pro, generates significant international interest. Rapid adoption within Korea further drives this.
Lee Byung-hwan, CEO of Sky Labs, confirmed discussions advanced during ESC Congress 2026 in Munich. These talks involved global pharmaceutical firms, medical device makers, contract research organizations, and distribution partners. Many discussions began before the congress. However, the company's accumulated clinical data moved them closer to concrete collaborations. Lee suggests these projects could progress faster than initially projected.
European Market Entry and Demand
Commercialization remains a primary focus for Sky Labs, particularly its European partnership with IEM. Sky Labs supplied products to IEM in the first half of this year. Devices are expected to reach the market during the second half of 2026. Interest observed at ESC 2026 indicated potential for swift demand.
Visitors to the Sky Labs booth inquired about purchasing devices in quantities of 100 or 200 units. Sky Labs directed these potential buyers to IEM, its European sales partner. Feedback from IEM’s distribution network has been encouraging, according to Lee, following their direct product experience at the congress.
Clinical Validation as a Differentiator
Sky Labs plans to enter the European market through both private-pay and reimbursement channels. Some markets allow ambulatory blood pressure monitoring outside public reimbursement, facilitating quicker entry via private clinics. Broader adoption in other markets, such as the UK, will depend on establishing reimbursement pathways.
Lee noted that reimbursement discussions are already underway and progressing faster than anticipated. Movement could occur before the end of this year, earlier than the initial expectation of early next year. The company emphasizes clinical evidence as crucial for its devices to be trusted and used in medical practice. This approach differentiates it from other wearable technology companies.
Implications for Asian Tech
Korea has served as a substantial proving ground for CART BP pro, which has accumulated numerous prescriptions quickly. This provides Sky Labs with real-world experience and clinical data. The company aims to leverage this for international expansion. For Asian beauty and health tech companies, Sky Labs' strategy demonstrates the critical role of robust clinical validation.
This is key for gaining market acceptance and accelerating global entry, especially in regulated medical fields. The approach of building evidence before reimbursement, as seen in Korea, offers a model for other Asian firms. This applies to developers of innovative health or beauty devices. Such devices require trust from medical professionals or consumers.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
